NCT00208923View on ClinicalTrials.gov

Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 31, 1998

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Hematologic Malignancies
Interventions
DRUG

Busulfan, Cyclophosphamide and Fludarabine

"* Bulsufan 1mg/kg/dose P.O. every 6 hours for 4 days. If intravenous, busulfan dose will be 0.8 mg/kg every 6 hours for 16 doses.~* Fludarabine 40 mg/m2 a day for 5 days via IV over 2 hours, dose based on weight.~* Cyclophosphamide given via IV over 1 hour at dose of 60 mg/kg/day for 2 consecutive days."

Trial Locations (1)

30322

Emory Universtiy Winship Cancer Institute, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT00208923 - Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies | Biotech Hunter | Biotech Hunter